Doppler ultrasound may be useful for patients with suspected GCA

Article

A study has found that doppler ultrasound may be useful in monitoring and diagnosis of patients with suspected giant cell arteritis (GCA).

A study has found that doppler ultrasound may be useful in monitoring and diagnosis of patients with suspected giant cell arteritis (GCA). The results are to be published in an issue of Clinical Ophthalmology.

Led by Dr Ana M. Suelves from La Fe University Hospital, Valencia, Spain, the researchers evaluated how useful ultrasound is in the diagnosis of GCA, in monitoring the response to corticotherapy and in detecting early relapses.

The study comprised 10 patients with suspected GCA who all underwent ultrasound examination of both temporal arteries before temporal artery biopsy (TAB), 3 weeks after starting treatment and 3 months after diagnosis. For the purposes of this study only histological findings were considered in defining whether the patients were suffering from GCA. All ultrasound results were compared with those from the biopsy and the best position to perform the biopsy was determined using ultrasound.

Using ultrasound, no false positive results were obtained and the results presented gave a sensibility, specificity and positive predictive value of 100% for the use of ultrasound in the diagnosis of GCA. Additionally, the researchers were able to detect two relapses early using ultrasound during the follow up period.

From the results it was concluded that the eco-doppler may be a useful tool in the diagnosis and clinical follow up of patients with suspected GCA.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.